MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host an analyst and institutional investor meeting on Wednesday, February 6, 2019, in New York City from 8:30 a.m. to approximately 10:30 a.m. Eastern Time. 

The meeting will include remarks from members of the Chembio leadership team on corporate strategy, operational initiatives, product development, collaborations and trends driving the business.

The meeting will be broadcast live via the internet, and a replay of the webcast will be available from 12:00 p.m. Eastern Time on February 6, 2019, through March 14, 2019. The live and recorded audio webcast of the meeting may be accessed at

About Chembio Diagnostics
Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Headquartered in Medford, NY, Chembio is registered with the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Learn more at

Media contact: 
Lynn Pieper Lewis
Gilmartin Group
(415) 937-5402